Analysts expect Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) to announce ($0.76) earnings per share for the current fiscal quarter, Zacks reports. Three analysts have provided estimates for Lexicon Pharmaceuticals’ earnings, with estimates ranging from ($0.80) to ($0.71). Lexicon Pharmaceuticals reported earnings of ($0.16) per share during the same quarter last year, which would indicate a negative year over year growth rate of 375%. The firm is expected to issue its next earnings results on Wednesday, March 11th.
On average, analysts expect that Lexicon Pharmaceuticals will report full-year earnings of $0.79 per share for the current year, with EPS estimates ranging from $0.71 to $0.87. For the next fiscal year, analysts forecast that the company will post earnings of ($2.10) per share, with EPS estimates ranging from ($2.40) to ($1.94). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of sell-side analysts that follow Lexicon Pharmaceuticals.
Lexicon Pharmaceuticals (NASDAQ:LXRX) last posted its quarterly earnings results on Thursday, November 7th. The biopharmaceutical company reported $2.11 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.31 by $0.80. Lexicon Pharmaceuticals had a return on equity of 2,372.40% and a net margin of 49.78%. The firm had revenue of $294.45 million for the quarter, compared to the consensus estimate of $12.00 million. During the same period in the previous year, the business earned ($0.26) earnings per share. The company’s revenue for the quarter was up 4124.5% compared to the same quarter last year.
LXRX has been the subject of a number of analyst reports. Zacks Investment Research cut Lexicon Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday. Gabelli cut Lexicon Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Wednesday, December 11th. They noted that the move was a valuation call. Wedbush reiterated a “buy” rating and issued a $17.00 target price on shares of Lexicon Pharmaceuticals in a research note on Sunday, December 22nd. Citigroup lowered Lexicon Pharmaceuticals from a “buy” rating to a “neutral” rating and upped their target price for the company from $3.00 to $4.00 in a research note on Friday, November 8th. Finally, ValuEngine upgraded Lexicon Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Friday, January 3rd. Eight analysts have rated the stock with a hold rating and one has given a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and an average target price of $6.50.
NASDAQ LXRX opened at $4.28 on Friday. Lexicon Pharmaceuticals has a fifty-two week low of $1.13 and a fifty-two week high of $8.39. The stock has a market cap of $428.28 million, a price-to-earnings ratio of 2.96 and a beta of 1.02. The business has a fifty day moving average of $4.22 and a 200-day moving average of $3.60. The company has a quick ratio of 8.01, a current ratio of 8.11 and a debt-to-equity ratio of 1.42.
Institutional investors have recently added to or reduced their stakes in the stock. Pictet Asset Management Ltd. boosted its holdings in Lexicon Pharmaceuticals by 9.6% in the third quarter. Pictet Asset Management Ltd. now owns 729,876 shares of the biopharmaceutical company’s stock valued at $2,197,000 after purchasing an additional 64,100 shares during the last quarter. Millennium Management LLC increased its stake in shares of Lexicon Pharmaceuticals by 4.5% in the third quarter. Millennium Management LLC now owns 1,220,629 shares of the biopharmaceutical company’s stock worth $3,674,000 after purchasing an additional 53,092 shares during the period. Vanguard Group Inc. increased its stake in shares of Lexicon Pharmaceuticals by 8.1% in the second quarter. Vanguard Group Inc. now owns 4,240,111 shares of the biopharmaceutical company’s stock worth $26,670,000 after purchasing an additional 319,382 shares during the period. Morgan Stanley increased its stake in shares of Lexicon Pharmaceuticals by 158.0% in the second quarter. Morgan Stanley now owns 195,307 shares of the biopharmaceutical company’s stock worth $1,229,000 after purchasing an additional 119,611 shares during the period. Finally, Russell Investments Group Ltd. bought a new position in shares of Lexicon Pharmaceuticals in the third quarter worth about $202,000. Hedge funds and other institutional investors own 96.24% of the company’s stock.
About Lexicon Pharmaceuticals
Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products. The company offers XERMELO, an orally-delivered small molecule drug candidate for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog therapy in adults.
Featured Article: What does RSI mean?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Lexicon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexicon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.